ERBB2 and breast carcinoma: In a subgroup of women diagnosed with a first breast cancer between 2010 and 2015 (follow-up through 2016), the 5-year cumulative incidence did not differ by HER2 status and the highest cumulative incidence was observed after a first triple-negative breast tumor (1.71%, 95% CI = 1.38–2.09%).